Longeveron Inc. (LGVN) stock
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.92−0.19 (-9.00%)
Close on Nov 18, 2026Market cap $61.21MP/E –Yield –
Longeveron operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Longeveron's operating cash flow for the twelve months ending Jun 30, 2026 was -$20.37M. For fiscal 2025 it was -$18.65M. The highest annual figure on record is -$2.36M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.65M | – |
| FY2024 | Dec 31, 2024 | -$13.87M | – |
| FY2023 | Dec 31, 2023 | -$19.00M | – |
| FY2022 | Dec 31, 2022 | -$13.97M | – |
| FY2021 | Dec 31, 2021 | -$9.64M | – |
| FY2020 | Dec 31, 2020 | -$2.36M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.65M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.28M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.03M | – |
| Q4 FY2020 | Dec 31, 2020 | -$505.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$233.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$398.00K | – |
See a number that looks wrong?